Chimeric antigen receptor (CAR) T-cell therapy is a way to get immune cells called T cells (a type of white blood cell) to fight cancer by changing them in the lab so they can find and destroy cancer ...

Design Therapeutics Inc. has described transcription modulators reported to be useful for the treatment of myotonic dystrophy type 1 (DM1) and Fuchs’ dystrophy.

ASX lithium stocks have surged as investors race to pick the bottom, following a lift in bargain basement lithium prices.

Myotonic dystrophy type 1 (DM1) is a rare disease where the highest prevalence is found in the small geographical region of Saguenay-Lac-St-Jean in Quebec, Canada. This disease impacts the quality of ...

Our T-Mobile vs. Verizon debate examines which phone carrier offers the best value, coverage, premium data, hotspots, and international features.

Northrop Grumman conducted the first test firing of its Booster Obsolescence and Life Extension (BOLE) five-segment solid rocket motor at its Promontory production and test site in Utah. The ...

Patients with residual invasive breast cancer receive standard T-DM1 treatment. Additional chemotherapy or hormone therapy may be administered as needed. Successful results from this trial could ...

The company also announced an updated plan for obtaining U.S. Accelerated Approval for DYNE-101 in DM1 following a Type C meeting with the FDA and analysis of new long-term functional data.

Antibody–drug conjugates (ADCs) are the conjugation of antibody with cytotoxic payloads. Conjugated peptides that originate from ADCs are commonly used for pharmacokinetics (PK) study. However, a ...

The revised trial protocol that means a delay in filing for U.S. approval of DYNE-101 to treat myotonic dystrophy type 1 (DM1) dented shares of Dyne Therapeutics Inc. (NASDAQ:DYN), which closed June ...